$75.6 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2022 |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-01-24
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-09 |
13F-HR | 2023-07-24 |
13F-HR | 2023-04-25 |
13F-HR | 2023-01-24 |
13F-HR | 2022-11-08 |
13F-HR | 2022-07-22 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.